Targeting the sonic hedgehog-Gli1 pathway as a potential new therapeutic strategy for myelodysplastic syndromes

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zou, Jixue ^a   Zhou, Zhigang ^a   Wan, Liping ^a   Tong, Yin ^a   Qin, Youwen ^a   Wang, Chun ^a   Zhou, Kun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; DNA METHYLTRANSFERASE 1; PROTEIN P15; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; AZACITIDINE; CDKN2B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE; GLI1 PROTEIN, HUMAN; SHH PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DISEASE COURSE; DNA SYNTHESIS INHIBITION; DRUG TARGETING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT TRANSFORMATION; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL SURVIVAL; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; AZACITIDINE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MALE; MICE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; YOUNG ADULT; ZINC FINGER PROTEIN GLI1;

EID: 84943329468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136843     Document Type: Article

References (32)

1. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. New England Journal of Medicine. 2009;361(19):1872-85. doi: 10.1056/NEJMra0902908 PMID: 19890130.
2. Aoki E, Uchida T, Ohashi H, Nagai H, Murase T, Ichikawa A, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia. 2000;14(4):586-93. Epub 2000/04/14. PMID: 10764143.
3. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172-9. Epub 2001/02/27. PMID: 11222358.
4. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91(8):2985-90. Epub 1998/05/16. PMID: 9531610.
5. Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leukemia & lymphoma. 1999;35(5-6):437-43. Epub 1999/12/28. doi: 10.1080/10428199909169608 PMID: 10609781.
6. Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene. 1999;18(20):3159-65. Epub 1999/05/26. doi: 10.1038/sj.onc.1202651 PMID: 10340388.
7. Uchida T, Kinoshita T, Hotta T, Murate T. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leukemia & lymphoma. 1998;32(1-2):9-18. Epub 1999/02/26. doi: 10.3109/10428199809059242 PMID: 10036997.
8. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90(4):1403-9. Epub 1997/08/15. PMID: 9269757.
9. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95(6):1942-9. Epub 2000/03/09. PMID: 10706859.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology. 2009;10(3):223-32. Epub 2009/02/24. doi: 10.1016/s1470-2045 (09) 70003-8 PMID: 19230772; PubMed Central PMCID: PMCPMC4086808.
11. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, Di Persio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-803. Epub 2006/03/15. doi: 10.1002/cncr.21792 PMID: 16532500.
12. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. The New England journal of medicine. 2003;349(21):2042-54. Epub 2003/11/25. doi: 10.1056/NEJMra023075 PMID: 14627790.
13. Bestor TH. The DNA methyltransferases of mammals. Human molecular genetics. 2000;9(16):2395-402. Epub 2000/09/27. PMID: 11005794.
14. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature. 2007;449(7159):248-51. Epub 2007/08/24. doi: 10.1038/nature06146 PMID: 17713477; PubMed Central PMCID: PMCPMC2712830.
15. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458(7239):776-9. Epub 2009/01/27. doi: 10.1038/nature07737 PMID: 19169242; PubMed Central PMCID: PMCPMC2946231.
16. Eichberger T, Sander V, Schnidar H, Regl G, Kasper M, Schmid C, et al. Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics. 2006;87(5):616-32. Epub 2006/01/26. doi: 10.1016/j.ygeno. 2005.12.003 PMID: 16434164.
17. Bai LY, Chiu CF, Lin CW, Hsu NY, Lin CL, Lo WJ, et al. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Leukemia. 2008;22(1):226-8. Epub 2007/10/12. doi: 10.1038/sj. leu.2404978 PMID: 17928882.
18. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001;2(2):172-80. Epub 2001/03/29. doi: 10.1038/84282 PMID: 11175816.
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302. Epub 2002/09/20. doi: 10.1182/blood-2002-04-1199 PMID: 12239137.
20. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65. Epub 2012/06/29. doi: 10.1182/blood-2012-03-420489 PMID: 22740453; PubMed Central PMCID: PMCPMC4425443.
21. Steube KG, Gignac SM, Hu ZB, Teepe D, Harms D, Kabisch H, et al. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leukemia & lymphoma. 1997;25(3-4):345-63. Epub 1997/04/01. doi: 10.3109/10428199709114174 PMID: 9168445.
22. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine. 2013;368(22):2059-74. Epub 2013/05/03. doi: 10.1056/NEJMoa1301689 PMID: 23634996; PubMed Central PMCID: PMCPMC3767041.
23. Abe S, Tsubouchi J, Takahashi K, Yamazaki M, Mizuno D. Combination therapy of murine tumors with lentinan plus lipopolysaccharide plus cyclophosphamide. Gan. 1982;73(6):961-7. Epub 1982/12/01. PMID: 7160585.
24. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer science. 2009;100(5):948-55. Epub 2009/02/28. doi: 10.1111/j.1349-7006.2009.01111.x PMID: 19245435.
25. Zou J, Hong Y, Tong Y, Wei J, Qin Y, Shao S, et al. Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem cells international. 2015;2015:957502. Epub 2015/04/11. doi: 10.1155/2015/957502 PMID: 25861282.
26. Hopfer O, Komor M, Koehler IS, Freitag C, Schulze M, Hoelzer D, et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leukemia research. 2009;33(3):434-42. Epub 2008/10/03. doi: 10.1016/j.leukres. 2008.08.014 PMID: 18829110.
27. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev. 2006;20(23):3215-31. Epub 2006/12/13. doi: 10.1101/gad.1464906 PMID: 17158741.
28. He S, Wang F, Yang L, Guo C, Wan R, Ke A, et al. Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PloS one. 2011;6(11):e27684. Epub 2011/11/24. doi: 10.1371/journal.pone.0027684 PMID: 22110720; PubMed Central PMCID: PMCPMC3215738.
29. Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, et al. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. British journal of haematology. 2001;112(1):148-54. Epub 2001/02/13. PMID: 11167795.
30. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in earlystage patients. European journal of haematology. 2006;76(1):23-32. Epub 2005/12/14. doi: 10.1111/j. 1600-0609.2005.00559.x PMID: 16343268.
31. Ma D, Fang Q, Wang P, Gao R, Sun J, Li Y, et al. Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15 (INK4B) promoter demethylation in myelodysplastic syndrome. Gene therapy. 2015;22(4):287-96. Epub 2015/02/06. doi: 10.1038/gt.2015.1 PMID: 25652099.
32. Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem. 2010;5(4):500-12. Epub 2010/03/17. doi: 10.1002/cmdc.201000011 PMID: 20229564.